Jump to content

Anthony Gordon (clinical scientist): Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
Cyeeber (talk | contribs)
28 edits
No edit summary
Tags: Visual edit Mobile edit Mobile web edit Disambiguation links added
Citation bot (talk | contribs)
Bots
5,010,343 edits
Alter: pages. Add: display-authors, s2cid, hdl, pmc, pmid, doi-access, authors 1-30. Formatted dashes. | Use this bot. Report bugs. | Suggested by Headbomb | #UCB_toolbar
Line 18: Line 18:
== Career and research ==
== Career and research ==


He undertook his postgraduate medical training in London with an additional year at The Royal North Shore Hospital in Sydney, Australia<ref>{{cite web |title=ICHT Consultant Directory |url=https://www.imperial.nhs.uk/consultant-directory/anthony-gordon |access-date=28 December 2023}}</ref> He was awarded the Intensive Care Society visiting fellowship in 2005 and spent two years in Vancouver at St Paul's [[Hospital]], [[University]] of British [[Columbia]]<ref>{{cite web |title=UBC Faculty and Fellows |url=https://ubccriticalcaremedicine.ca/faculty/dr-keith-walley/ |access-date=28 December 2023}}</ref> and also worked as the director of medical development of a university spin-out company (Sirius Genomics) developing pharmacogenetic tests for use in the ICU.<ref>{{cite journal |last1=Annane |first1=Djillali |last2=Mira |first2=Jean Paul |last3=Ware |first3=Lorraine B |last4=Gordon |first4=Anthony C |last5=Sevransky |first5=Jonathan |last6=Stüber |first6=Frank |last7=Heagerty |first7=Patrick J |last8=Wellman |first8=Hugh F |last9=Neira |first9=Mauricio |last10=Mancini |first10=Alexandra DJ |last11=Russell |first11=James A |title=Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated) |journal=Annals of Intensive Care |date=December 2012 |volume=2 |issue=1 |doi=10.1186/2110-5820-2-15}}</ref>
He undertook his postgraduate medical training in London with an additional year at The Royal North Shore Hospital in Sydney, Australia<ref>{{cite web |title=ICHT Consultant Directory |url=https://www.imperial.nhs.uk/consultant-directory/anthony-gordon |access-date=28 December 2023}}</ref> He was awarded the Intensive Care Society visiting fellowship in 2005 and spent two years in Vancouver at St Paul's [[Hospital]], [[University]] of British [[Columbia]]<ref>{{cite web |title=UBC Faculty and Fellows |url=https://ubccriticalcaremedicine.ca/faculty/dr-keith-walley/ |access-date=28 December 2023}}</ref> and also worked as the director of medical development of a university spin-out company (Sirius Genomics) developing pharmacogenetic tests for use in the ICU.<ref>{{cite journal |last1=Annane |first1=Djillali |last2=Mira |first2=Jean Paul |last3=Ware |first3=Lorraine B |last4=Gordon |first4=Anthony C |last5=Sevransky |first5=Jonathan |last6=Stüber |first6=Frank |last7=Heagerty |first7=Patrick J |last8=Wellman |first8=Hugh F |last9=Neira |first9=Mauricio |last10=Mancini |first10=Alexandra DJ |last11=Russell |first11=James A |title=Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated) |journal=Annals of Intensive Care |date=December 2012 |volume=2 |issue=1 |doi=10.1186/2110-5820-2-15|doi-access=free |pmid=22694772 }}</ref>


As an NIHR Research Professor (2016-2022)<ref>{{cite web |title=Current NIHR Research Professors |url=https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758#round-6-2016 |website=www.nihr.ac.uk |language=EN}}</ref> he leads a multi-disciplinary team investigating the use of ‘omic techniques<ref>{{cite journal |last1=Antcliffe |first1=David B. |last2=Burnham |first2=Katie L. |last3=Al-Beidh |first3=Farah |last4=Santhakumaran |first4=Shalini |last5=Brett |first5=Stephen J. |last6=Hinds |first6=Charles J. |last7=Ashby |first7=Deborah |last8=Knight |first8=Julian C. |last9=Gordon |first9=Anthony C. |title=Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial |journal=American Journal of Respiratory and Critical Care Medicine |date=15 April 2019 |volume=199 |issue=8 |pages=980–986 |doi=10.1164/rccm.201807-1419OC}}</ref> and artificial intelligence (AI)<ref>{{cite journal |last1=Komorowski |first1=Matthieu |last2=Celi |first2=Leo A. |last3=Badawi |first3=Omar |last4=Gordon |first4=Anthony C. |last5=Faisal |first5=A. Aldo |title=The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care |journal=Nature Medicine |date=November 2018 |volume=24 |issue=11 |pages=1716–1720 |doi=10.1038/s41591-018-0213-5}}</ref> to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies.
As an NIHR Research Professor (2016-2022)<ref>{{cite web |title=Current NIHR Research Professors |url=https://www.nihr.ac.uk/documents/current-nihr-research-professors/21758#round-6-2016 |website=www.nihr.ac.uk |language=EN}}</ref> he leads a multi-disciplinary team investigating the use of ‘omic techniques<ref>{{cite journal |last1=Antcliffe |first1=David B. |last2=Burnham |first2=Katie L. |last3=Al-Beidh |first3=Farah |last4=Santhakumaran |first4=Shalini |last5=Brett |first5=Stephen J. |last6=Hinds |first6=Charles J. |last7=Ashby |first7=Deborah |last8=Knight |first8=Julian C. |last9=Gordon |first9=Anthony C. |title=Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial |journal=American Journal of Respiratory and Critical Care Medicine |date=15 April 2019 |volume=199 |issue=8 |pages=980–986 |doi=10.1164/rccm.201807-1419OC|pmid=30365341 |pmc=6467319 }}</ref> and artificial intelligence (AI)<ref>{{cite journal |last1=Komorowski |first1=Matthieu |last2=Celi |first2=Leo A. |last3=Badawi |first3=Omar |last4=Gordon |first4=Anthony C. |last5=Faisal |first5=A. Aldo |title=The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care |journal=Nature Medicine |date=November 2018 |volume=24 |issue=11 |pages=1716–1720 |doi=10.1038/s41591-018-0213-5|hdl=10044/1/61246 |s2cid=53025350 }}</ref> to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies.


He is the [[United Kingdom|UK]] [[Chief]] Investigator for the REMAP-CAP clinical trial<ref>{{cite web |title=REMAP-CAP Trial |url=https://www.remapcap.org/ |website=REMAP-CAP Trial}}</ref>, which was the first trial to demonstrate that the immune modulating drugs, tocilizumab and sarilumab, saved lives from severe COVID-19.<ref>{{cite web |title=Arthritis drug effective in treating sickest COVID-19 patients {{!}} Imperial News {{!}} Imperial College London |url=https://www.imperial.ac.uk/news/209033/arthritis-drug-effective-treating-sickest-covid-19/ |website=Imperial News |language=en |date=19 November 2020}}</ref> The Prime Minister announced this result from 10 Downing Street<ref>{{cite web |title=Prime Minister's statement on coronavirus (COVID-19): 7 January 2021 |url=https://www.gov.uk/government/speeches/prime-ministers-statement-on-coronavirus-covid-19-7-january-2021 |website=GOV.UK |language=en |date=7 January 2021}}</ref> and Gordon is the first author of the published paper.<ref>{{cite journal |title=Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=22 April 2021 |volume=384 |issue=16 |pages=1491–1502 |doi=10.1056/NEJMoa2100433}}</ref> This trial has reported on more than a dozen other interventions for severe COVID-19, including hydrocortisone, convalescent plasma, anti-virals, anti-platelet drugs<ref>{{cite journal |title=Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial |journal=JAMA |date=2023 |volume=329 |issue=1 |pages=39-51 |doi=10.1001/jama.2022.23257}}</ref>, therapeutic heparin<ref>{{cite journal |title=Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=26 August 2021 |volume=385 |issue=9 |pages=777–789 |doi=10.1056/NEJMoa2103417}}</ref><ref>{{cite journal |title=Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=26 August 2021 |volume=385 |issue=9 |pages=790–802 |doi=10.1056/NEJMoa2105911}}</ref>, ACE inhibitors and Angiotensin Receptor Blockers (ARBs)<ref>{{cite journal |title=Effect of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized with COVID-19: A Randomized Clinical Trial |journal=JAMA |date=2023 |volume=329 |issue=14 |pages=1183-1196 |doi=10.1001/jama.2023.4480}}</ref>, high-dose vitamin C<ref>{{cite journal |title=Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials |journal=JAMA |date=2023 |volume=330 |issue=18 |pages=1745-1759 |doi=10.1001/jama.2023.21407}}</ref> and simvastatin<ref>{{cite journal |title=Simvastatin in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=21 December 2023 |volume=389 |issue=25 |pages=2341–2354 |doi=10.1056/NEJMoa2309995}}</ref>. The trial has now been selected by the NIHR as the national platform trial to find the most effective treatments for people hospitalised with severe flu.<ref>{{cite web |title=New study will help rapidly find flu treatments this winter |url=https://www.nihr.ac.uk/news/new-study-will-help-rapidly-find-flu-treatments-this-winter/32076 |website=www.nihr.ac.uk |language=EN}}</ref>
He is the [[United Kingdom|UK]] [[Chief]] Investigator for the REMAP-CAP clinical trial<ref>{{cite web |title=REMAP-CAP Trial |url=https://www.remapcap.org/ |website=REMAP-CAP Trial}}</ref>, which was the first trial to demonstrate that the immune modulating drugs, tocilizumab and sarilumab, saved lives from severe COVID-19.<ref>{{cite web |title=Arthritis drug effective in treating sickest COVID-19 patients {{!}} Imperial News {{!}} Imperial College London |url=https://www.imperial.ac.uk/news/209033/arthritis-drug-effective-treating-sickest-covid-19/ |website=Imperial News |language=en |date=19 November 2020}}</ref> The Prime Minister announced this result from 10 Downing Street<ref>{{cite web |title=Prime Minister's statement on coronavirus (COVID-19): 7 January 2021 |url=https://www.gov.uk/government/speeches/prime-ministers-statement-on-coronavirus-covid-19-7-january-2021 |website=GOV.UK |language=en |date=7 January 2021}}</ref> and Gordon is the first author of the published paper.<ref>{{cite journal |title=Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=22 April 2021 |volume=384 |issue=16 |pages=1491–1502 |doi=10.1056/NEJMoa2100433|pmid=33631065 |hdl=10044/1/86283 |s2cid=230798728 }}</ref> This trial has reported on more than a dozen other interventions for severe COVID-19, including hydrocortisone, convalescent plasma, anti-virals, anti-platelet drugs<ref>{{cite journal |title=Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial |journal=JAMA |date=2023 |volume=329 |issue=1 |pages=39–51 |doi=10.1001/jama.2022.23257 |last1=Florescu |first1=Simin |last2=Stanciu |first2=Delia |last3=Zaharia |first3=Mihaela |last4=Kosa |first4=Alma |last5=Codreanu |first5=Daniel |last6=Kidwai |first6=Aneela |last7=Masood |first7=Sobia |last8=Kaye |first8=Callum |last9=Coutts |first9=Amanda |last10=MacKay |first10=Lynn |last11=Summers |first11=Charlotte |last12=Polgarova |first12=Petra |last13=Farahi |first13=Neda |last14=Fox |first14=Eleonore |last15=McWilliam |first15=Stephen |last16=Hawcutt |first16=Daniel |last17=Rad |first17=Laura |last18=o'Malley |first18=Laura |last19=Whitbread |first19=Jennifer |last20=Jones |first20=Dawn |last21=Dore |first21=Rachael |last22=Saunderson |first22=Paula |last23=Kelsall |first23=Olivia |last24=Cowley |first24=Nicholas |last25=Wild |first25=Laura |last26=Thrush |first26=Jessica |last27=Wood |first27=Hannah |last28=Austin |first28=Karen |last29=Bélteczki |first29=János |last30=Magyar |first30=István |pmid=36525245 |pmc=9857594 |display-authors=1 }}</ref>, therapeutic heparin<ref>{{cite journal |title=Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=26 August 2021 |volume=385 |issue=9 |pages=777–789 |doi=10.1056/NEJMoa2103417|pmid=34351722 |author1=REMAP-CAP Investigators |author2=ACTIV-4a Investigators |author3=ATTACC Investigators |last4=Goligher |first4=E. C. |last5=Bradbury |first5=C. A. |last6=McVerry |first6=B. J. |last7=Lawler |first7=P. R. |last8=Berger |first8=J. S. |last9=Gong |first9=M. N. |last10=Carrier |first10=M. |last11=Reynolds |first11=H. R. |last12=Kumar |first12=A. |last13=Turgeon |first13=A. F. |last14=Kornblith |first14=L. Z. |last15=Kahn |first15=S. R. |last16=Marshall |first16=J. C. |last17=Kim |first17=K. S. |last18=Houston |first18=B. L. |author19=Derde LPG |last20=Cushman |first20=M. |last21=Tritschler |first21=T. |last22=Angus |first22=D. C. |last23=Godoy |first23=L. C. |last24=McQuilten |first24=Z. |last25=Kirwan |first25=B. A. |last26=Farkouh |first26=M. E. |last27=Brooks |first27=M. M. |last28=Lewis |first28=R. J. |last29=Berry |first29=L. R. |last30=Lorenzi |first30=E. |pmc=8362592 |display-authors=1 }}</ref><ref>{{cite journal |title=Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=26 August 2021 |volume=385 |issue=9 |pages=790–802 |doi=10.1056/NEJMoa2105911|hdl=10044/1/90873 |s2cid=236927358 }}</ref>, ACE inhibitors and Angiotensin Receptor Blockers (ARBs)<ref>{{cite journal |title=Effect of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized with COVID-19: A Randomized Clinical Trial |journal=JAMA |date=2023 |volume=329 |issue=14 |pages=1183–1196 |doi=10.1001/jama.2023.4480|pmid=37039790 }}</ref>, high-dose vitamin C<ref>{{cite journal |title=Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials |journal=JAMA |date=2023 |volume=330 |issue=18 |pages=1745–1759 |doi=10.1001/jama.2023.21407|pmid=37877585 }}</ref> and simvastatin<ref>{{cite journal |title=Simvastatin in Critically Ill Patients with Covid-19 |journal=New England Journal of Medicine |date=21 December 2023 |volume=389 |issue=25 |pages=2341–2354 |doi=10.1056/NEJMoa2309995|pmid=37888913 |author1=REMAP-CAP Investigators |last2=Hills |first2=T. E. |last3=Lorenzi |first3=E. |last4=Berry |first4=L. R. |last5=Shyamsundar |first5=M. |last6=Al-Beidh |first6=F. |last7=Annane |first7=D. |last8=Arabi |first8=Y. |last9=Aryal |first9=D. |last10=Au |first10=C. |last11=Beane |first11=A. |last12=Bhimani |first12=Z. |last13=Bonten |first13=M. |last14=Bradbury |first14=C. A. |last15=Brunkhorst |first15=F. M. |last16=Burrell |first16=A. |last17=Buxton |first17=M. |last18=Calfee |first18=C. S. |last19=Cecconi |first19=M. |last20=Cheng |first20=A. C. |last21=Cove |first21=M. E. |last22=Detry |first22=M. A. |last23=Estcourt |first23=L. J. |last24=Fitzgerald |first24=M. |last25=Goligher |first25=E. C. |last26=Goossens |first26=H. |last27=Green |first27=C. |last28=Haniffa |first28=R. |last29=Harrison |first29=D. A. |last30=Hashmi |first30=M. |s2cid=264501247 |display-authors=1 }}</ref>. The trial has now been selected by the NIHR as the national platform trial to find the most effective treatments for people hospitalised with severe flu.<ref>{{cite web |title=New study will help rapidly find flu treatments this winter |url=https://www.nihr.ac.uk/news/new-study-will-help-rapidly-find-flu-treatments-this-winter/32076 |website=www.nihr.ac.uk |language=EN}}</ref>


==Honours==
==Honours==

Revision as of 22:40, 28 December 2023

Anthony Christopher Gordon
NationalityBritish
Scientific career
FieldsCritical Care Sepsis
InstitutionsImperial College London
Thesis Genetic polymorphisms of the innate immune system: influence on susceptibility and outcome in severe sepsis and septic shock
Doctoral advisorCharles Hinds
Websitewww.imperial.ac.uk/people/anthony.gordon

Professor Anthony Gordon FRCA FFICM FMedSci is a British clinician scientist and the Chair of Anaesthesia & Critical Care at Imperial College London and works as an intensive care consultant at Imperial College Healthcare NHS Trust.[1]. He uses innovative research methods to improve & individualise care of acutely ill patients.

Early life and education

Educated at Kings College School, Wimbledon[2] he studied medicine at St Bartholomew’s Hospital Medical School, University of London and was awarded a BSc in Anatomy with Basic Medical Sciences in 1990 and MBBS in 1993. He undertook his doctoral studies with Charles Hinds and was awarded an MD for his thesis exploring genetic polymorphisms in sepsis[3]

Career and research

He undertook his postgraduate medical training in London with an additional year at The Royal North Shore Hospital in Sydney, Australia[4] He was awarded the Intensive Care Society visiting fellowship in 2005 and spent two years in Vancouver at St Paul's Hospital, University of British Columbia[5] and also worked as the director of medical development of a university spin-out company (Sirius Genomics) developing pharmacogenetic tests for use in the ICU.[6]

As an NIHR Research Professor (2016-2022)[7] he leads a multi-disciplinary team investigating the use of ‘omic techniques[8] and artificial intelligence (AI)[9] to improve outcomes in sepsis, with a particular focus on clinical trials and translational studies.

He is the UK Chief Investigator for the REMAP-CAP clinical trial[10], which was the first trial to demonstrate that the immune modulating drugs, tocilizumab and sarilumab, saved lives from severe COVID-19.[11] The Prime Minister announced this result from 10 Downing Street[12] and Gordon is the first author of the published paper.[13] This trial has reported on more than a dozen other interventions for severe COVID-19, including hydrocortisone, convalescent plasma, anti-virals, anti-platelet drugs[14], therapeutic heparin[15][16], ACE inhibitors and Angiotensin Receptor Blockers (ARBs)[17], high-dose vitamin C[18] and simvastatin[19]. The trial has now been selected by the NIHR as the national platform trial to find the most effective treatments for people hospitalised with severe flu.[20]

Honours

His contributions to clinical science have been recognised in appointment as a Fellow of the Academy of Medical Sciences (2022)[21], an Honorary Member of the Intensive Care Society[22] and NIHR Senior Investigator (2023)[23]

References

  1. ^ "Personal Imperial Webpage". Retrieved 28 December 2023.
  2. ^ "Old Kings Club newsletter" (PDF). Retrieved 28 December 2023.
  3. ^ Gordon, Anthony. Genetic polymorphisms of the innate immune system : influence on susceptibility and outcome in severe sepsis and septic shock. Queen Mary, University of London.
  4. ^ "ICHT Consultant Directory". Retrieved 28 December 2023.
  5. ^ "UBC Faculty and Fellows". Retrieved 28 December 2023.
  6. ^ Annane, Djillali; Mira, Jean Paul; Ware, Lorraine B; Gordon, Anthony C; Sevransky, Jonathan; Stüber, Frank; Heagerty, Patrick J; Wellman, Hugh F; Neira, Mauricio; Mancini, Alexandra DJ; Russell, James A (December 2012). "Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)". Annals of Intensive Care. 2 (1). doi:10.1186/2110-5820-2-15. PMID 22694772.
  7. ^ "Current NIHR Research Professors". www.nihr.ac.uk.
  8. ^ Antcliffe, David B.; Burnham, Katie L.; Al-Beidh, Farah; Santhakumaran, Shalini; Brett, Stephen J.; Hinds, Charles J.; Ashby, Deborah; Knight, Julian C.; Gordon, Anthony C. (15 April 2019). "Transcriptomic Signatures in Sepsis and a Differential Response to Steroids. From the VANISH Randomized Trial". American Journal of Respiratory and Critical Care Medicine. 199 (8): 980–986. doi:10.1164/rccm.201807-1419OC. PMC 6467319. PMID 30365341.
  9. ^ Komorowski, Matthieu; Celi, Leo A.; Badawi, Omar; Gordon, Anthony C.; Faisal, A. Aldo (November 2018). "The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care". Nature Medicine. 24 (11): 1716–1720. doi:10.1038/s41591-018-0213-5. hdl:10044/1/61246. S2CID 53025350.
  10. ^ "REMAP-CAP Trial". REMAP-CAP Trial.
  11. ^ "Arthritis drug effective in treating sickest COVID-19 patients | Imperial News | Imperial College London". Imperial News. 19 November 2020.
  12. ^ "Prime Minister's statement on coronavirus (COVID-19): 7 January 2021". GOV.UK. 7 January 2021.
  13. ^ "Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19". New England Journal of Medicine. 384 (16): 1491–1502. 22 April 2021. doi:10.1056/NEJMoa2100433. hdl:10044/1/86283. PMID 33631065. S2CID 230798728.
  14. ^ Florescu, Simin; et al. (2023). "Long-term (180-Day) Outcomes in Critically Ill Patients With COVID-19 in the REMAP-CAP Randomized Clinical Trial". JAMA. 329 (1): 39–51. doi:10.1001/jama.2022.23257. PMC 9857594. PMID 36525245.
  15. ^ REMAP-CAP Investigators; et al. (26 August 2021). "Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19". New England Journal of Medicine. 385 (9): 777–789. doi:10.1056/NEJMoa2103417. PMC 8362592. PMID 34351722.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  16. ^ "Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19". New England Journal of Medicine. 385 (9): 790–802. 26 August 2021. doi:10.1056/NEJMoa2105911. hdl:10044/1/90873. S2CID 236927358.
  17. ^ "Effect of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized with COVID-19: A Randomized Clinical Trial". JAMA. 329 (14): 1183–1196. 2023. doi:10.1001/jama.2023.4480. PMID 37039790.
  18. ^ "Intravenous vitamin C for patients hospitalized with COVID-19: two harmonized randomized clinical trials". JAMA. 330 (18): 1745–1759. 2023. doi:10.1001/jama.2023.21407. PMID 37877585.
  19. ^ REMAP-CAP Investigators; et al. (21 December 2023). "Simvastatin in Critically Ill Patients with Covid-19". New England Journal of Medicine. 389 (25): 2341–2354. doi:10.1056/NEJMoa2309995. PMID 37888913. S2CID 264501247.
  20. ^ "New study will help rapidly find flu treatments this winter". www.nihr.ac.uk.
  21. ^ "BRC researchers awarded AMS Fellowships – NIHR Imperial Biomedical Research Centre".
  22. ^ "ICS Members meeting 2023". X.com.
  23. ^ "NIHR appoints new Senior Investigators, including seven Imperial BRC researchers – NIHR Imperial Biomedical Research Centre". Retrieved 28 December 2023.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Anthony_Gordon_(clinical_scientist)&oldid=1192354757"